Betamimetics in fetal distress: randomised controlled trial.
The objective of the study was to investigate if a single dose of Hexoprenaline administered to patients diagnosed as having fetal distress improves neonatal outcome and whether there are any side effects and complications related to hexoprenaline injection. Patients with fetal distress diagnosed by electronic fetal heart rate monitoring with a gestational age of 35 weeks or more in active labor were eligible. Once the decision to deliver the patient by Cesarean section was made, patients were approached and randomised by sealed opaque envelopes to hexoprenaline or control groups. Ten micrograms of hexoprenaline were administered intravenously to study patients. Main outcomes were cord blood gas values, Apgar scores, the need for resuscitation and admission to intensive care. There were no statistically significant differences in the main outcome measures between the two groups. Fewer babies in the hexoprenaline group had a pH of < 7.2 and a base excess of < -10, but this was not statistically significant. The fetal heart rate pattern was improved in significantly more patients after hexoprenaline administration than controls. In conclusion, despite the statistically significant improvement in fetal heart rate tracings, Apgar scores and blood gas values showed only a trend towards improvement in the hexoprenaline group.
Kulier
R
R
Department of Obstetrics and Gynecology, Coronation/JG Strijdom, Johannesburg, South Africa.
Gülmezoĝlu
A M
AM
Hofmeyr
G J
GJ
Van Gelderen
C J
CJ
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D005260:Female; D005316:Fetal Distress / Q000188:drug therapy*; D006340:Heart Rate, Fetal; D006594:Hexoprenaline / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D016896:Treatment Outcome
D000318:Adrenergic beta-Agonists; D006594:Hexoprenaline